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Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by an elevated red cell mass caused by excessive myelopoiesis with propensity to transformation to myelofibrosis and acute leukemia.
1 JAK2 V617F mutation 2 and acquired uniparental disomy on chromosome 9p (9p UPD) 3, 4 are the most frequent somatic alterations. JAK2 is mutated in over 90% of PV patients; 2 however, in spite of its prevalence it is regarded as necessary but not sufficient to cause the disease. 5 Yet, systematic mutation analysis of exome coding sequence has to be described. We here analyzed 31 JAK2
V617F
-positive patients by whole-exome sequencing and single nucleotide polymorphism array and further investigated the mutational evolution using longitudinal samples collected from seven patients (Supplementary Methods).
Whole-exome sequencing targeting B43 Mb of coding sequence yielded an average of 125-fold coverage (Supplementary Figure 1) , with 95% of targeted bases covered to a depth of Â 20 (Supplementary Figure 2) . In this study, we use the exomes of T cells as a reference genome and we defined sequence variants present in granulocytes but not in the T cells from the same patient as somatic mutations. DNA copy-number analysis revealed multiple recurrent chromosomal arm-length changes including 9p UPD, trisomy of 9p and 1q, LOH at 18p and single patients with 2p and 9q LOH, trisomy 2q and UPD at 22q. Through serial sampling, we observed a focal hemizygous deletion in PV28 (Supplementary Figure 3) at 9q22.31-32. No known tumor suppressors or oncogenes were found in this region and its functional importance is unclear at this time.
We validated 87 somatic non-silent mutations and a subset of important germline variants (Supplementary Table 1 ). The average non-silent somatic mutation rate was 0.08 per megabase, which was much lower than other adult cancers.
6 G-4T transversion was the most frequent base change, followed by C-4T transition (Supplementary Figure 4) . The recurrent G1849T mutation leading to JAK2 V617F accounted for the majority of G-4T transversions as all patients harbored JAK2 V617F . The most frequently mutated class of genes ( Figure 1 ) was that involved in epigenetic modification. Forty-two percent of patients had at least one somatic mutation in an epigenetic modifier, indicating that epigenetic regulation has a key role in PV pathogenesis, as it does in other myeloid neoplasms. Many other known cancer-related genes were mutated in single patients as shown in Figure 1 .
Recurrent somatic mutations were observed in: ASXL1, DNMT3A, TET2, SF3B1 and PDE4C (Figure 1 ). ASXL1 belongs to the Enhancer of trithorax and Polycomb gene families, which are responsible for maintaining activation and silencing of PcG and trxG proteins. 7 Disruption of ASXL1, through inactivating mutations in exon 12 is prevalent in post-PV myelofibrosis, but is identified only rarely in cases of essential thrombocytosis or PV. 8 Stein and co-workers sequenced exon 12 of ASXL1 in 42 PV cases but found only one patient (2%) with a nonsense mutation. 8 We identified four inactivating somatic mutations in ASXL1 (12.9%), two frame-shift and two nonsense. All four loss-of-function mutations were identified in exon 12. This was a sixfold higher mutation rate than previously reported 9 and is similar to other myeloproliferative neoplasm. Somatic DNMT3A mutations were reported at low frequency in PV (2.7%). 10 The reported mutations were identified in the terminal exon, at position M880 and R882. In this study, we identified three somatic DNMT3A mutations (9.7%), one was identified at the known hotspot, R882, and the other two were novel frame-shift mutations at codon K456. SF3B1 encodes subunit 1 of the splicing factor 3b, which is important for anchoring the spliceosome to precursor mRNA. Mutation of SF3B1 is frequent in most myeloproliferative neoplasm, having been reported in myelodysplasia with ring sideroblasts (65%), 9 myelodysplastic syndrome (20%), 9 primary myelofibrosis (7%) 11 and essential thombocythemia (3%), but it has not been reported in PV. 9 In this study, we identified three SF3B1 mutations in two patients (9.7%), patient PV5 carried two mutations and both were reported by COSMIC (http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/). Interestingly, phosphodiesterase 4C, PDE4C, is mutated in two patients. PDE4C hydrolyzes the second messenger cAMP and therefore mediates a variety of responses to extracellular signals. Although mutation in this gene is rarely observed in cancer, one of the mutations we discovered was reported in COSMIC, suggesting it may be functionally relevant.
The fraction of reads with a given mutation, the variant allele fraction, is proportional to the number of nuclei in the tumor sample harboring the mutation. As the granulocytes in PV patients are clonal as determined by X-inactivation in females, 12 the variant allele fraction of the mutations reported in Figure 1 , should correspond to the order in which they appeared in the patient. Three patients, PV5, PV8 and PV24, exhibited tumor variant allele fraction in the key epigenetic modifier genes, ASXL1, DNMT3A or SF3B1 that were higher than JAK2 V617F ( Figure 2a ). Interestingly mutation in a gene associated with immunosuppression in solid tumors, IDO1, is also found at higher variant allele burden than that of JAK2 V617F . These results suggest that mutation of these genes might have preceded the acquisition of JAK2 V617F . In seven patients, we could determine the order of appearance of mutations directly by longitudinal sampling (Figure 2b ). Patients PV1, PV3, PV8, PV10, PV23 and PV29 harbored only JAK2 V617F mutation in 2011. Upon follow-up in 2013, four of them had acquired additional mutations, particularly in key epigenetic modifier genes DNMT3A, SMARCA2 and TET2, but also in SF3B1, STK11, CDH3 and TP53. One patient harbored IDH2 and JAK2 in 2011, but did not acquire any additional mutations. Results from a parallel study of these patients showed that 10% of them acquired 9p UPD prior to JAK2 V617F mutations (Figure 1 , Group III patients), whereas 42% had acquired JAK2 V617F mutation first ( Figure 1 , Group II, AMBER13-LEU-1191).
Novel sequence variants found in both granulocytes and T cells from the same patients are putative germline mutations. However, in seven patients, these putative germline variants were in genes that were somatically mutated in other patients in the cohort (Figure 1, blue tiles) . Moreover, a high proportion of these so-called germline mutations were likely to be functionally Gene   PV24  PV21  PV16  PV26  PV28  PV3  PV23  PV1  PV8  PV5  PV31  PV25  PV6  PV22  PV4  PV15  PV2  PV9  PV12  PV27  PV10  PV17  PV13  PV18  PV7  PV20  PV29  PV19  PV14  PV30 II II  II II  II  II II II  II II II   Granulocytes only Granulocytes + T-cells Figure 1 . Summary of somatic mutations, germline variants and somatic DNA copy-number alterations identified in 31 PV cases. Somatic mutations were shown in orange and red based on their mutation type and germline variants were shown in blue. For germline variants, only those frame-shift variants, nonsense variants or those variants reported in COSMIC database (http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/) were shown and only those genes with somatic mutations identified in the cohort were listed. The total number of somatic mutations identified per patient and gene was showed at the top and right, respectively. The allelic fraction of JAK2 V617F was shown at the top row and color scaled. The group classification was based on the relationship of JAK2 V617F and 9p aUPD. Subgroup I, patients harbored JAK2 V617F in a heterozygous state without detectable 9p aUPD; subgroup II, patients had JAK2 V617F with an allelic fraction in direct proportion to the level of 9p aUPD; subgroup III, patients harbored 9p aUPD at approximately twice the level of the JAK2 V617F allelic burden. The clinical data were summarized at the bottom. CNAs, somatic DNA copy-number alterations: T, trisomy; L, hemizygous deletion; U, uniparental disomy. Transformation: M, myelofibrosis. Spleen size: 0, the size of spleen is not palpable; 1, o3 cm; 2, o6 cm; 3, 46 cm. Stage: 1, low; 2, intermediate; 3, high. Response to therapy: 0, no response; 1, partial response; 2, complete response. Gender: M, male; F, female. relevant either because they were truncating frameshift or nonsense mutations or the same mutations could be found in COSMIC. For example, the tumor suppressor NF1 was mutated in four patients' T cells and granulocytes. Among them, three variants are presented in COSMIC. Germline mutation of NF1 is linked to neurofibromatosis type 1, a debilitating dominant genetic disorder characterized by a higher risk for juvenile myelomonocytic leukemia with a potential progression to acute myeloid leukemia. 13 Symptoms of neurofibromatosis type 1 were not observed in our PV patients, thus it is highly unlikely these patients have true germline mutation in this gene. Similar variants were also found in two patients in ASXL1, and one patient each in TET2, DNMT3A and IDH2. The IDH2 variant R140Q is a hotspot for somatic mutation in acute myeloid leukemia and other cancers. On the basis of these results, NF1 emerges as a frequently mutated gene (16%) in PV; ASXL1 mutated in 19% of patients, fivefold higher than previously reported (P ¼ 0.02, Fisher's exact test); and DNMT3A and TET2 each mutated in 13% of our cohort.
These mutations could not be explained by contamination of the T cells by granulocytes because the T cells harbored little or no JAK2
, whereas these mutations are present in similar variant allele fractions in the T cells and granulocytes (Supplementary Figure 5) . Therefore, we conclude these were somatic mutations in long-lived T cells. For the mutations to have populated both the T-cell and granulocyte lineages in equal proportions, they must have occurred in pluripotent stem cells early in the lives of these patients, well before the JAK2 V617F mutation that favors myeloid differentiation. The involvement of T cells by some of the somatic mutations was unexpected. Studies based on the distribution of X-chromosome allelic usage have been used to assess the relative contribution of pluripotent stem cells to B-and T-cell lymphopoiesis versus myelopoiesis. Indeed, in normal healthy females the X-chromosome allelic usage of myeloid and lymphoid progeny was identical suggesting that these are all derived from relative small number of hematopoietic stem cells present in female embryo at the time of X-chromosome inactivation.
14 However, the majority of T cells, unlike myeloid progeny in PV are polyclonal 15 suggesting that the mutations observed were derived from stem cells prior to the clonal event necessary for discernible PV phenotype. However, a small proportion of T cells may be part of the PV clone, 3 and JAK2 V617F mutant cells have preferentially myeloid potential but not exclusively as some JAK2 V617F lymphoid progeny are also formed. 16 In this report, we present a novel observation that some pre-JAK2 V617F somatic mutations contribute to substantial T-lymphocyte progeny.
In summary, we sequenced 31 PV pairs of granulocytes and T cells presumed to have germline genome and identified multiple novel driver genes and pre-JAK2 mutations and described the signatures of clonal evolution during PV progression in some patients. This study contributes to our understanding of the pathogenesis of PV and underscores the complexity of genetic lesions in the typical PV genome. 
JAK2
V617F mutation is the most common somatic event observed in patients with myeloproliferative neoplasms (MPN).
1-4 JAK2
V617F
is found in over 95% of patients with polycythemia vera (PV), 55% of essential thrombocytosis and 65% of primary myelofibrosis (MF). Homozygous JAK2 V617F is present in about half of PV patients, whereas it is rarely seen in other MPNs. 3, 5, 6 Patients bearing homozygous JAK2 V617F tend to have a longer duration of disease, 2 higher hemoglobin levels, increased incidence of pruritis 7 and are more likely to progress to post-PV MF. 8 Homozygous JAK2 V617F is shown to result from mitotic recombination, leading to acquired uniparental disomy (aUPD) on chromosome 9p. 9 It was reported that JAK2 46/1 (GGCC) haplotype may predispose carriers to JAK2 mutation, [10] [11] [12] and JAK2
facilitates the acquisition of homozygous JAK2. 9, 13 Challenging this view was a single study reporting 9p aUPD in two PV subjects with wild-type JAK2, 14 suggesting that in these two individuals, 9p aUPD might have preceded JAK2 V617F . However, the relationship between JAK2 V617F and 9p aUPD, the frequency and stability of existing PV genotypes has yet to be systematically defined in a larger PV cohort. To address this, we performed whole-exome sequencing and SNP array in 31 PV patients, and further validated our findings in two additional cohorts totaling 59 patients (Supplementary Methods). In addition, we investigated the stability of PV genotypes using 36 longitudinal samples.
The allelic fraction of JAK2 V617F in granulocytes (GNC), measured by sequencing, varied from 0.01 to 1.0 (Figure 1 ). 9p aUPD spanning JAK2 locus was present in 48% of patients in the discovery set. The fraction of genomes harboring 9p aUPD in a given GNC sample, varied from 0.08 to 1.0 (Figure 1) . On the basis of quantitative relationship between JAK2 V617F allelic fraction and the fraction of genomes harboring 9p aUPD, we defined four PV subgroups and validated this finding in extended two cohorts (Figure 1 ). Across the three cohorts, 42% of patients harbored JAK2 V617F in a heterozygous state without detectable 9p aUPD (subgroup I); 45% of patients had JAK2
V617F with an allelic fraction in direct proportion to the level of 9p aUPD (subgroup II; homozygous JAK2 V617F ); 10% of patients harbored 9p aUPD at approximately twice the level of the JAK2 V617F allelic burden (subgroup III; aUPD with heterozygous JAK2 V617F ). Although any single patient in subgroup III, taken in isolation, could be explained as a mixture of cells from subgroups I and II, the best explanation for the pattern of subgroup III across these patients is that JAK2
V617F and 9p aUPD reside in the same cell with heterozygous JAK2
V617F in all such patients. Thus, subgroup III reported in this study comprises a novel subtype that has not been previously described. Three patients (3%) exhibited trisomy of 9p, generating two copies of JAK2 V617F allele (subgroup IV). The number of patients in subgroup IV was too small and thus this group was not evaluated further.
We then investigated the stability of each PV genotype using longitudinal samples. The JAK2 V617 :9p aUPD ratio remained stable in 11 of 17 patients, although the JAK2 V617 allele burden
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